NYSE:CRLLife Sciences
Should Charles River (CRL) Leadership Shift and M&A Push Reshape Its Innovation-Led Growth Strategy?
In January 2026, Charles River Laboratories announced a planned CEO transition to long-time executive Birgit Girshick, expanded its M&A pipeline, including deals for K.F. (Cambodia) Ltd. and the remaining stake in PathoQuest SAS, and highlighted improving Discovery and Safety Assessment demand with incremental cost savings and solid financing capacity for further acquisitions.
The appointment of former FDA Principal Deputy Commissioner Dr. Namandjé N. Bumpus as Chief Scientific and...